News headlines about Madrigal Pharmaceuticals (NASDAQ:MDGL) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Madrigal Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.0816873163707 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Madrigal Pharmaceuticals (NASDAQ MDGL) opened at 45.95 on Friday. The stock has a 50 day moving average price of $36.09 and a 200 day moving average price of $21.08. The company’s market cap is $574.15 million. Madrigal Pharmaceuticals has a 12 month low of $13.09 and a 12 month high of $52.35.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.09). Analysts anticipate that Madrigal Pharmaceuticals will post ($2.67) earnings per share for the current fiscal year.
MDGL has been the subject of several analyst reports. Evercore ISI initiated coverage on Madrigal Pharmaceuticals in a report on Friday, September 22nd. They set an “outperform” rating and a $65.00 target price for the company. JMP Securities increased their target price on Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the company an “outperform” rating in a report on Friday, October 13th. Finally, Roth Capital initiated coverage on Madrigal Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $62.00 target price for the company.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/28/madrigal-pharmaceuticals-mdgl-getting-somewhat-favorable-news-coverage-analysis-shows.html.
In other news, Director Richard S. Levy purchased 2,000 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The stock was purchased at an average price of $16.12 per share, for a total transaction of $32,240.00. Following the completion of the acquisition, the director now owns 7,200 shares of the company’s stock, valued at $116,064. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard S. Levy purchased 3,550 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The stock was purchased at an average price of $16.12 per share, with a total value of $57,226.00. Following the acquisition, the director now directly owns 3,640 shares of the company’s stock, valued at approximately $58,676.80. The disclosure for this purchase can be found here. Insiders purchased 9,100 shares of company stock valued at $145,840 in the last quarter. 66.40% of the stock is owned by company insiders.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.